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The ability of certain man-made chemicals to mimic
the effects of natural steroid hormones and their poten-
tial to disrupt the delicate balance of the endocrine sys-
tem in animals are of increasing concern. The growing
list of reported hormone-mimics includes the alkylphe-
nolic (AP) compounds, a small number of which have
been reported to be weakly estrogenic. In their most
basic form, APs are composed of an alkyl group, which
can vary in size, branching, and position, joined to a
phenolic ring. The aim of this project was to identify the
important structural features responsible for the estro-
genic activity of AP chemicals. This was achieved by
incubating APs with different structural features in a
medium containing a previously described estrogen-in-
ducible strain of yeast (Saccharomyces cerevisiae) ex-
pressing the human estrogen receptor and comparing
their activity spectrophotometrically by the resulting
color change of the medium. The results were compared
to the effects of the main natural estrogen 17b-estradiol.
The data indicate that both the position (para > meta >
ortho) and branching (tertiary> secondary 5 normal) of
the alkyl group affect estrogenicity. Optimal estrogenic
activity requires a single tertiary branched alkyl group
composed of between 6 and 8 carbons located at the
para position on an otherwise unhindered phenol ring.
The results are discussed in relation to the purity and
composition of the chemicals tested.
In the early 1930s, scientists began synthesizing compounds
based on the phenanthrene nucleus of steroidal estrogens in an
attempt to produce substances with similar properties and
considerable clinical value. Estrogenic activity was assessed by
subcutaneous administration of chemicals (dissolved in sesame
oil) to ovariectomized rats that were then observed for the onset
of estrus (1). It soon became apparent that the phenanthrene
condensed ring structure was not required for estrogenic activ-
ity, with the discovery that diphenyl and diphenyl methane
derivatives (2) and stilbene derivatives (3–6) containing two
hydroxyl groups in the para positions (e.g. 4,49-dihydroxy di-
phenyl) were also active. The substituted derivative of stilbene
(4,49-dihydroxystilbene) was renamed stilbestrol and was used
as the parent compound in the production of another series of
estrogenic compounds, including 4,49-dihydroxydiethylstilbene
(later known as diethylstilbestrol), which is still one of the most
potent man-made estrogens. During this period, the first ref-
erences to active compounds containing only one benzene ring,
such as para-hydroxy propenyl benzene (anol) (7) and some of
the alkylphenolic compounds, are found (8). It seems that this
information was long forgotten, until it recently resurfaced
within the context of endocrine disruption.
Some members of a surprisingly large group of natural and
man-made chemicals are estrogenic (9–17). The unforeseen
biological activity and exposure to man-made xenoestrogens
have been implicated in the increased incidence of certain
cancers and also with various disorders of the male reproduc-
tive system, including reduced testicular size and sperm pro-
duction in humans and wildlife (18, 19), through both direct
(receptor-mediated) and indirect actions on the endocrine sys-
tem. For example, dioxins produce physiological responses in
vivo similar to those seen by administration of potent synthetic
estrogens and antiestrogens, without interacting directly with
the estrogen receptor (17). In receptor binding studies and
transfected chicken embryo fibroblast (CEF) cells, alkylphenols
have been shown to interact with the estrogen receptor directly
(20) and act in an identical way to 17b-estradiol in stimulating
receptor transcription (21).
One pathway via which exposure of the developing male
fetus to xenoestrogens could result in reduced testicular size
and sperm production in adult life has been proposed. Ultimate
testicular size and fertility of adult animals is determined
shortly after testicular differentiation by the final number of
Sertoli cells present. Exposure of the fetus to estrogens at this
critical time point could reduce the number of Sertoli cells.
Recent studies with rats (22) and rainbow trout (23) have
demonstrated an inhibition of testicular growth after exposure
to alkylphenolic chemicals. These findings support the conten-
tion that exposure to low levels of weakly estrogenic environ-
mental chemicals, including alkyphenols, could affect gonadal
development in the fetus. In view of this, it is important to isolate
the structural features responsible for the activity of xenoestro-
gens, so that chemicals with similar features can be identified.
In this study we have screened alkylphenolic compounds of
known structure for estrogenicity using a previously described
recombinant yeast screen (24). Shifts in potency derived from
specific structural changes are used to identify the important
structural features responsible for their activity.
MATERIALS AND METHODS
The Recombinant Yeast—Details of the estrogen-inducible expres-
sion system in yeast and preparation of the medium components have
been described previously (24). In brief, the DNA sequence of the
human estrogen receptor was integrated into the yeast genome, which
also contained expression plasmids carrying estrogen-responsive se-
quences controlling the expression of the reporter gene Lac-Z (encoding
the enzyme b-galactosidase). Thus, in the presence of estrogens, b-ga-
lactosidase is synthesized and secreted into the medium, where it
breaks down the chromogenic substrate chlorophenol red-b-D-galacto-
pyranoside (CPRG),1 which is initially yellow, into a red product that
can be measured by absorbance.
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Assay Procedure—As described previously in Routledge and Sumpter
(24), stock solutions of alkylphenolic chemicals and the estradiol stand-
ard were serially diluted in ethanol, and 10-ml aliquots of each concen-
tration were transferred in duplicate to optically flat 96-well microtiter
plates and allowed to evaporate to dryness. Aliquots (200 ml) of the
assay medium containing recombinant yeast and the chromogenic sub-
strate CPRG were then dispensed to each sample well. Each plate
contained at least one row of blanks (assay medium only). Possible
spurious results resulting from conversion of the CPRG by the chemi-
cals alone was addressed by incubating identical plates in assay me-
dium without yeast. The plates were sealed with autoclave tape and
shaken vigorously for 2 min on a titer plate shaker before incubation at
32 °C. After an 84-h incubation, the color of the medium was read at an
absorbance of 540 nm (using a Titertek Multiskan MCC/340 plate
reader). At this stage, control wells (blanks) appeared light orange in
color, due to background expression of b-galactosidase, and turbid, due
to growth of the yeast. Positive wells were indicated by a deep red color
with turbid yeast growth. Clear yellow wells indicated lysis (a toxic
response), and the color may vary. All data were corrected for turbidity
using a second reading at 620 nm. The plates were left at room tem-
perature for an additional 7 days and observed for possible enzyme-
inhibiting action, indicated by responses below background.
Assay Validation—The specificity of the screen was determined us-
ing steroids purchased from Sigma. Stock solutions (2 3 1027 M) were
made in ethanol, and all serial dilutions were carried out in ethanol to
achieve final concentrations of 1 3 1028 to 5 3 10212 M in the microtiter
wells. The ability of the yeast screen to detect known environmental
estrogens has been described previously in Routledge and Sumpter (24).
To demonstrate that the chemicals tested were acting through the
estrogen receptor, the ability of tamoxifen, an estrogen antagonist
known to act via the estrogen receptor, to inhibit the activity of the
alkylphenolic chemicals was investigated. A 40 mM stock solution of
tamoxifen (Aldrich) was serially diluted in ethanol, and 10-ml aliquots
of each concentration were transferred in duplicate to optically flat
96-well microtiter plates and allowed to evaporate to dryness. Aliquots
(200 ml) of the assay medium containing recombinant yeast, the chro-
mogenic substrate CPRG, and 17b-estradiol (or alkylphenolic chemical)
were then dispensed to each sample well. The concentration of 17b-
estrogen added to the medium was sufficient to produce an obvious, but
not maximal, response. Controls were assay medium alone (largest
attainable response) and assay medium without the addition of estra-
diol or alkylphenols (normal background expression), which was also
incubated concurrently with tamoxifen. The plates were sealed with
autoclave tape and shaken vigorously for 2 min on a titer plate shaker
before incubation at 32 °C. After an 84-h incubation, the color of the
medium was read at an absorbance of 540 nm. At this stage, medium
without 17b-estradiol or alkylphenolic chemicals appeared light orange
in color, due to background expression of b-galactosidase, and turbid,
due to growth of the yeast. Wells containing only 17b-estradiol or
alkylphenolic chemicals appeared red in color, due to increased synthe-
sis of b-galactosidase. The antiestrogenic activity of tamoxifen was
observed as a dose-dependent inhibition of the color change of the
medium from yellow to red.
Chemicals Tested—Alkylphenolic chemicals with particular struc-
tural features were obtained from commercial and industrial sources
and assessed for estrogenic activity. Chemicals tested were chosen on
the basis of purity and knowledge of their composition. The activities of
alkylphenolic chemicals were compared to the effects of the main nat-
ural estrogen 17b-estradiol (purchased from Sigma). A 200 nM stock of
17b-estradiol was prepared in ethanol, after which serial dilutions were
carried out to produce final concentrations of 10 nM to 5 pM in the wells.
The alkylphenolic compounds 4-methylphenol (99% pure), 4-ethyl-
phenol (99% pure), 4-propylphenol (99% pure), 3-tert-butylphenol (99%
pure), 4-tert-butylphenol (99% pure), and 4-tert-amylphenol (99% pure)
were purchased from Aldrich. 2-phenylphenol (99% pure), 3-phenylphe-
nol (99% pure), and 4-phenylphenol (99% pure) were purchased from
MTM (Lancashire, United Kingdom). 2-tert-butylphenol (99% pure),
2-sec-butylphenol (99% pure), 4-sec-butylphenol (98% pure), 4-n-pentyl-
phenol (98% pure), 4-tert-hexylphenol (99% pure), 4-tert-heptylphenols
(80% pure, 15% 2-tert-heptylphenols), 4-n-heptylphenol (98% pure),
2-tert-octylphenol (99% pure), 4-tert-octylphenol (98% pure), 2-nonyl-
phenol (95% pure), 4-nonylphenol (95% pure), 2-sec-decylphenol (98%
pure), 4-sec-decylphenol (90% pure), 2,4 di-nonylphenol (75% pure, 25%
4-nonylphenol), 2-methyl 4-nonylphenol (.95% pure), and 4-methyl
2-nonylphenol (95% mixed isomers) were supplied by Schenectady In-
ternational, Inc. (Schenectady, NY). 4-nonylphenol diethoxylate (4NP 1
2EO; 95% pure), propoxylated 4-nonylphenol (4NP 1 1.5PO; 95% pure),
4-sec-dodecylphenol (95% pure), 4-sec-dodecylphenol dipropoxylate (4-
DDP 1 2PO; 95% pure) were supplied by Witco (Houston, TX). Stock
solutions of the chemicals were made up in ethanol, after which serial
dilutions were carried out to achieve final concentrations of between 5
mM and 60 nM in the wells.
Relative Potencies—The estrogenic activity of alkylphenolic chemi-
cals was assessed by dividing the concentration of the chemical produc-
ing a half-maximal response by the concentration of 17b-estradiol re-
quired to produce the same response. The data presented in this paper
were the product of a single assay to ensure a fair representation of the
potencies of the chemicals relative to one another.
RESULTS
Validation of the Recombinant Yeast Screen—The specificity
of the screen was assessed by the ability of a range of steroids
and steroid metabolites, diluted from 1 3 1028 M, to stimulate
synthesis of b-galactosidase in the yeast. The data presented in
Fig. 1 show that the strongest response was seen in the wells
containing 17b-estradiol. The next most potent steroids were
estrone, the man-made estrogen diethylstilbestrol, 17a-estra-
diol, and estriol, which had potencies approximately 2, 4, 40,
and 300 times less than that of 17b-estradiol, respectively. All
the other steroids failed to induce b-galactosidase activity.
Sensitivity and reproducibility were assessed by measuring the
response of the screen to triplicate dilutions of 17b-estradiol,
over a concentration of 3072 ng/liter to 1.5 ng/liter, compared to
triplicates with assay medium only. Variance did not exceed
0.5% of each mean value at each point across the dilution
range, and a detectable increase in b-galactosidase production
was consistently produced with 2 ng of 17b-estradiol/liter.
Assay Response to Known Environmental Estrogens—The
response of the screen to genistein (phytoestrogen), bisphe-
nol-A (epoxy resin precursor), and o, p9-DDT (pesticide) tested
over a concentration range of 100 mg/liter to 50 mg/liter has
been reported previously in Routledge and Sumpter (24). All
produced a dose-dependent elevation in b-galactosidase pro-
duction. Thus, the assay is capable of detecting known
xenoestrogens.
Inhibition of 17b-estradiol and Alkylphenolic Chemicals by
Tamoxifen—The ability of the antiestrogen tamoxifen to inhibit
the effect of 17b-estradiol and alkylphenolic chemicals was
FIG. 1. Specificity of the estrogen screen for a range of steroids
and steroid metabolites. The graph depicts the log concentration of
17b-estradiol (M), estrone (), estriol (), 17a-estradiol (l), 17b-estra-
diol glucuronide (f), testosterone (E), cortisol (x), 4-hydroxy progester-
one (1), and diethylstilbestrol (L), all serially diluted from 1 3 1028 M,
plotted against the absorbance (A540) of the medium after a 3-day
incubation. Maximal responses at the highest concentrations are not
shown. In most cases the S.E. was too small to illustrate. The blank (l)
illustrates the background absorbance of the medium.
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used to illustrate the requirement of these compounds to inter-
act with the estrogen receptor to stimulate the synthesis of
b-galactosidase. Yeast cells were incubated in the presence and
absence of 17b-estradiol, 4-sec-butylphenol, 4-n-heptylphenol,
and 4-tert-octylphenol at concentrations required to produce a
distinct, but not maximal, synthesis of b-galactosidase and
concurrently with varying concentrations of tamoxifen. Fig. 2
illustrates that in the absence of 17b-estradiol or alkylphenolic
compounds, the final background absorbance of the medium
(A540) remained at approximately 0.9. In the presence of 17b-
estradiol or alkylphenolic chemicals, the increased synthesis of
b-galactosidase elevated the absorbance of the medium to ap-
proximately 2.0 during the same incubation period. Wells in
which the chemicals were incubated together with tamoxifen
all showed a dose-dependent inhibition of expression of b-ga-
lactosidase, indicating that all the compounds are acting via
the estrogen receptor. Tamoxifen on its own behaved as a weak
partial agonist,2 producing a maximal stimulatory response
(approximately half that produced by 17b-estradiol) at a con-
centration 4 orders of magnitude greater than that of
17b-estradiol.
Estrogenicity of Alkylphenolic Chemicals—After having pre-
viously assessed the response of the screen to a variety of
natural and synthetic estrogens, we proceeded to test alkylphe-
nolic chemicals with different structural features for estrogenic
activity. All the compounds were tested over a concentration
range of 5 mM down to 60 nM. There was no indication that any
of the chemicals reacted with the CPRG or affected the per-
formance of the enzyme. Different structural features of alkyl-
phenolic chemicals were assessed for their ability to confer
estrogenic activity.
Size of the Alkyl Group—Fig. 3 shows the effect of increasing
alkyl group size of 4-tert substituted alkylphenolic chemicals on
estrogenic activity. The small alkyl group size of 4-methylphe-
nol and 4-ethylphenol (1 and 2 carbons, respectively) means
these exist only as normal branching forms. 4-propylphenol (3
carbons) exists only as normal and secondary branched forms.
4-methylphenol and 4-ethylphenol did not stimulate b-galacto-
sidase production in the yeast; however, 4-propylphenol (3 car-
bons in the alkyl group) produced a weak response (20,000,0002 E. J. Routledge and J. P. Sumpter, unpublished result.
FIG. 2. Inhibition of 17b-estradiol and alkylphenolic chemicals by tamoxifen. Yeast cells were incubated in the absence (E) or presence
(L) of alkylphenolic chemicals and concurrently with varying doses of tamoxifen (M). The yeast cells were incubated with: A, 2.5 3 10210 M
17b-estradiol (L); B, 2 3 1024 M 4-sec-butylphenol (L); C, 1 3 1025 M 4-n-heptylphenol (L); and D, 1 3 1026 M 4-tert-octylphenol (L) either alone
or concurrently with tamoxifen (M) at various concentrations.
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times less potent than estradiol). The response increased with
each additional carbon, up to a maximum of 8 carbon atoms,
but all were much less potent than 17b-estradiol: 4-tert-butyl-
phenol (4 carbons; 1,500,000-fold less potent), 4-tert-amylphe-
nol (5 carbons; 100,000-fold less potent), 4-tert-hexylphenol (6
carbons; 6,000-fold less potent), 4-tert-heptylphenol (7 car-
bons; 3,000-fold less potent), and 4-tert-octylphenol (8 car-
bons; 1,000-fold less potent). Activity seems to decrease when
the carbon number exceeds 8 because 4-nonylphenol (9 car-
bons; 30,000-fold less potent) was 30 times less potent than
4-tert-octylphenol.
Degree of Branching of the Alkyl Group—Fig. 4 compares the
effect of 4-secondary and 4-tertiary alkyl group branching
structures on estrogenic activity. Chemicals with both types of
branching structure stimulated b-galactosidase production in
the yeast and therefore are estrogenic in vitro. 4-tert-butylphe-
nol was approximately 1,500,000 times less potent than 17b-
estradiol and 2.5 times more potent than its secondary
branched equivalent (Fig. 4A). 4-tert-octylphenol was 1,000
times less potent than 17b-estradiol and 60 times more potent
than its secondary branched equivalent (Fig. 4B). This indi-
cates that tertiary branching structures are more active in
vitro and that potency increases with increasing alkyl group
size irrespective of the type of branching. 4-tert-octylphenol
was 1,500 times more potent than 4-tert-butylphenol, whereas
4-sec-octylphenol was only 65 times more potent than 4-sec-
butylphenol, indicating that secondary branched structures
have a more limited potency range in vitro compared to 4-tert
equivalents.
Fig. 5 compares 4-normal (unbranched) alkylphenolic chem-
icals to their 4-tert branched equivalents. Chemicals with both
types of branching were active, but in this case the trend was
not so well defined. Of the normal branched structures avail-
able, the most potent was 4-n-amylphenol, which was approx-
imately 30,000 times less potent than estradiol and about 3
times more potent than its 4-tert equivalent (Fig. 5A). The
addition of 2 carbons to the alkyl group reversed this pattern
because 4-tert-heptylphenol was approximately 3,000 times
less potent than estradiol and 25 times more potent than its
normal branched equivalent (Fig. 5B).
Fig. 6 summarizes the relative potency of all the 4-branched
APs tested compared to 17b-estradiol. In general, 4-tertiary
branching structures containing 6–8 carbons are approxi-
mately 30 times more potent than 4-normal and 4-secondary
equivalents, which are similar in potency in vitro. Estrogenic-
ity increases with alkyl group size up to 8 carbons (tertiary), or
between five and six carbons (normal and secondary), after
which it appears to decrease (tertiary), or remain fairly con-
stant up to 10 carbons (normal and secondary). This plateau in
activity observed by the normal and secondary branching forms
may not continue indefinitely, as 4-sec-dodecylphenol, contain-
ing 12 carbons in the alkyl group, was 100-fold less active than
the 10 carbon equivalent.
Position of the Alkyl Group on the Phenol Ring—Fig. 7 shows
the effect of positional changes of alkylation on estrogenic
FIG. 3. Response of the estrogen screen to a range of 4-substi-
tuted tertiary-branched alkylphenolic compounds of varying
alkyl group size. The graphs depict the log concentration of 17b-
estradiol (j) serially diluted from 10 nM to 5 pM and alkylphenolic
chemicals diluted to produce concentrations between 5 mM and 60 nM
plotted against the absorbance of the medium after a 3-day incubation.
Maximal responses at the highest concentrations are not shown. The
yeast cells were incubated with 4-methylphenol (1), 4-ethylphenol (n),
4-propylphenol (E), 4-butylphenol (l), 4-amylphenol (), 4-hexylphenol
(), 4-heptylphenol (f), 4-octylphenol (M), and 4-nonylphenol (x). The
blank (l) depicts the basal level of expression in the assay.
FIG. 4. Response of the estrogen screen to 4-substituted alkyl-
phenolic compounds that vary in their alkyl group branching.
The yeast cells were incubated with (A) 4-tert-butylphenol (l) and
4-sec-butylphenol (L). B, 4-tert-octylphenol () and 4-sec-octylphenol
() at concentrations ranging from 5 mM to 60 nM. Maximal responses
at the highest concentrations are not shown.
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potency. Fig. 7A shows that 2 (ortho)- and 3 (meta)-tert-butyl-
phenol did not stimulate b-galactosidase production in the
screen and therefore possess no detectable estrogenic activity.
4-tert-butylphenol produced a dose-dependent response from
5 3 1025 M, making it approximately 1,500,000 times less
potent than 17b-estradiol. 4-tert-octylphenol was 1,000 times
less potent than 17b-estradiol and 10,000 times more potent
than the 2-tert equivalent (Fig. 7B). 4-sec-decylphenol was
100,000 times less potent than estradiol (Fig. 7C), whereas no
observable activity was detected with 2-sec-decylphenol
(.100,000K times less potent than 17b-estradiol). This indi-
cates that the alkyl group must be at the para or 4th position
on the phenol ring relative to the hydroxyl group for optimal
estrogenic activity. The slight response seen with 2-tert-octyl-
phenol may be attributed to the higher potency that this size
alkyl group gives to the molecule compared to the other alkyl-
phenolic chemicals tested. It is possible that 2- and 3-tert-
butylphenol and 2-sec-decylphenol are also estrogenic, but that
they must be present in the assay in many grams/liter to
produce a response; that is, if they are active, they are ex-
tremely weak estrogens.
Effect of Methylation—Fig. 8 illustrates the effect of adding
of a small nonestrogenic methyl group (see Fig. 6) onto the
phenolic ring of an existing AP. Addition of a methyl group to
the second (ortho) position on the phenolic ring of 4-nonylphe-
nol did not affect the activity because 2-methyl 4-nonylphenol
and 4-nonylphenol were both approximately 30,000 times less
potent than 17b-estradiol. If the alkyl groups change position
so that the methyl group is in the 4th position and the nonyl
group is in the 2nd position, there is a 33-fold reduction in
activity. 2-nonylphenol is about 3 times less potent than 4-non-
ylphenol (data not shown), so the addition of the methyl group
in the para position was responsible for an additional 11-fold
reduction in activity not attributable to the positional change of
the nonyl (9-carbon alkyl) group alone. Moreover, 3-methyl
2-nonylphenol (in which the methyl group is at themeta or 3rd
position) and 2-nonylphenol are equipotent (data not shown).
This indicates that the para or 4th position (opposite the hy-
droxyl group on the phenolic ring) is an important feature for
estrogenicity because activity is reduced only when this posi-
tion, rather than another position, is methylated.
Effect of Di-Substitution—Fig. 9 illustrates the effect of di-
substitution on estrogenic activity. However, interpretation of
these results is complicated by the fact that that the 2,4-di-
nonylphenol was not pure; it contained about 25% “free” non-
ylphenol. The response produced by the 2,4-di-nonylphenol
may be entirely attributable to the nonylphenol in the sample.
It is possible, therefore, that 2,4-di-nonylphenol has no intrin-
sic activity. 2,4-di-butylphenol (99% pure) and 2,6-di-butylphe-
nol (99% pure) both failed to stimulate b-galactosidase produc-
tion in the assay (data not shown). It therefore seems likely
that di-substitution (or addition of another alkyl group larger
than a methyl group) greatly reduces or completely abolishes
estrogenic activity.
Effect of Altering the Size and Branching of the Ethoxylate
Side Chain—Fig. 10 shows the effect of ethoxylate chain length
and branching on estrogenic potency of 4-substituted alkylphe-
nolic compounds. The short chain ethoxylates are particularly
relevant because they are some of the main breakdown prod-
ucts of nonionic surfactants. Fig. 10A shows that the addition of
2 ethoxylates to 4-nonylphenol results in a 165-fold reduction
in activity, indicating that a free ring hydroxyl group is re-
quired for optimal activity. Moreover, addition of a branched
propylene oxide group results in at least a 35,000-fold reduc-
tion in activity because no b-galactosidase production was ob-
served. Fig. 10B indicates that the same is true for secondary
FIG. 5. Response of the estrogen screen to 4-substituted alkyl-
phenolic compounds that vary in their alkyl group branching.
The yeast cells were incubated with (A) 4-n-amylphenol (M) and 4-tert-
amylphenol (f). B, 4-tert-heptylphenol () and 4-n-heptylphenol () at
concentrations ranging from 5 mM to 60 nM.
FIG. 6. Relative potency of 4-substituted alkylphenolic com-
pounds with varying alkyl group size and branching compared
to the main natural estrogen 17b-estradiol.
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branched alkylphenolic chemicals because the addition of two
propylene oxide groups to 4-sec-dodecylphenol results in a com-
plete loss of activity over the concentration range tested.
Estrogenic Activity of Different Isomers of Phenylphenol—
Many of the features required for estrogenic activity of alkyl-
phenolic chemicals may apply to other groups of chemicals,
such as those composed of two benzene rings. Fig. 11 again
illustrates the importance of positional changes on estrogenic-
ity in three phenylphenol derivatives. Analogous to the situa-
tion observed with alkylphenolic chemicals, the most active
derivative (4-phenylphenol) is 20,000 times less potent than
17b-estradiol and bears the phenyl group opposite to the hy-
droxyl group. Each successive movement of the phenyl group
around the phenolic ring results in an approximately 7-fold
reduction in activity.
DISCUSSION
A large number of test systems now exist to identify estro-
genic activity. These include traditional bioassays relying on
relatively complex biological responses, such as stimulation of
water imbibition, uterine growth and vaginal cornification in
ovariectomized laboratory rodents (16, 25), and the expression
of the egg yolk precursor vitellogenin in male oviparous verte-
FIG. 7. The effect of positional changes in alkylation on the
estrogenic potency of alkylphenolic compounds in the yeast
screen. The yeast cells were incubated with (A) 4-tert-butylphenol (L),
3-tert-butylphenol (), and 2-tert-butylphenol (). B, 4-tert-octylphenol
(f) and 2-tert-octylphenol (M). C, 4-sec-decylphenol (l) and 2-sec-decyl-
phenol (E) at concentrations ranging from 5 mM to 60 nM.
FIG. 8. The effect of a single point ring methylation on the
estrogenic potency of alkylphenolic compounds in the yeast
screen. The yeast cells were incubated with 4-nonylphenol (x),
2-methyl 4-nonylphenol (), and 4-methyl 2-nonylphenol () at concen-
trations ranging from 5 mM to 60 nM.
FIG. 9. The effect of di-substitution on the estrogenic potency
of alkylphenolic compounds in the yeast screen. The yeast cells
were incubated with 4-nonylphenol (f) and 2,4 di-nonylphenol (M) at
concentrations ranging from 5 mM to 60 nM.
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brates (26, 27), in vitro assays including hepatocyte cell cul-
tures (11), and proliferation of MCF-7 breast cancer cell lines
(28) and some crystallographic and computer modeling studies
(29, 30). More recently, the advancement of molecular biology
has allowed the production of recombinant systems. In these
systems, the DNA sequence of the estrogen receptor is stably
integrated and expressed in host cells that also contain re-
porter genes that monitor the activity of the receptor by the
production of easily quantifiable end points, such as the expres-
sion of an enzyme or the production of light by luciferase
(31–33).
In vitro studies using a range of different cell lines and
transfection assays have shown that certain xenoestrogens can
produce biological responses similar to 17b-estradiol itself, al-
beit only when present at a 1,000- to 100 million-fold greater
concentration. The actual discovery of many weak xenoestro-
gens in vitro relies on the simple fact that these systems com-
bine extreme sensitivity with the ability to operate over an
extremely large concentration range (34).
The information available on the estrogenic activity of alkyl-
phenolic chemicals in vitro and in vivo is surprisingly consist-
ent, despite species differences in affinity of receptors for 17b-
estradiol (35) and variations in uptake, bioavailability, and
metabolism in different systems. In accordance with our find-
ings (Fig. 3), early experiments by Dodds and Lawson (8) indi-
cated that a single 100-mg dose of 4-tert-amylphenol (4-tert-
pentylphenol) was more potent than 4-tert-butylphenol.
Contrary to our results, however, none of the 4-normal (un-
branched) alkylphenolic compounds (except the propyl deriva-
tives) were active at the same dose, possibly due to metabolic
conversion to nonestrogenic derivatives in vivo. The method of
administration (the vehicle and route of administration) may
also affect the response to certain xenoestrogens (8).
Data derived from fish (hepatocyte culture), avian (CEF
cells), and mammalian (MCF-7) systems (21, 28) are also con-
cordant with our findings. All agree that 4-tert-octylphenol is
approximately 10-fold more potent than 4-nonylphenol and
between 103 and 104 times less potent than 17b-estradiol. This
suggests that species differences in the amino acid sequence of
the estrogen receptor are likely to occur in regions that are not
important for AP binding. The discoveries that 4-ethylphenol
was inactive, but 4-propylphenol produced a weak proliferative
response in MCF-7 cell culture, and that 4-sec and 4-tert-bu-
tylphenol were equipotent and over 10 times less potent than
4-nonylphenol (28) also correspond to our findings (see Figs. 3
and 4A).
The basic molecular mechanisms of hormone-dependent
transcription activation by the human estrogen receptor in
mammalian cells (including DNA binding, hormone binding,
nuclear localization, and transcriptional enhancement of a
gene bearing estrogen-responsive sequences) have been shown
to operate in yeast (36). Yeast-based systems have, therefore,
been widely used to establish the mechanisms of ligand bind-
ing, as well as dissecting receptor function and transcriptional
activation using site-directed mutagenesis (37–39). In vitro
tests, however, represent only a part of the metabolic system
present in entire animals and may not illustrate the effect of
bioconcentration, both of which may affect estrogenic potency.
Thus, the potency of a chemical in vitro may not be relevant to
an in vivo situation. Chemicals identified as being estrogenic in
vitro should therefore be tested in in vivo studies retrospec-
tively. The advantages and limitations of yeast-based systems
are discussed in Routledge and Sumpter (24).
The prerequisite of alkylphenolic compounds to interact with
the estrogen receptor to stimulate the production of b-galacto-
sidase in this system was tested by incubating the yeast cells in
FIG. 10. The effect of ethoxylate chain length and branching
on the estrogenic potency of 4-substituted alkylphenolic com-
pounds in the yeast screen. The yeast cells were incubated with (A)
4-nonylphenol (), 4-nonylphenol diethoxylate (l) and propoxylated
4-nonylphenol (V). B, 4-sec-dodecylphenol () and 4-sec-dodecylphenol
dipropoxylate (), at concentrations ranging from 5 mM to 60 nM.
FIG. 11. Compounds with two phenol rings. The yeast cells were
incubated with 4-phenylphenol (f), 3-phenylphenol (), and 2-phenyl-
phenol () at concentrations ranging from 800 mM to 200 nM.
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the absence or presence of alkylphenols together with the an-
tiestrogen tamoxifen. Tamoxifen has been shown to be a com-
petitive inhibitor of estradiol binding to estrogen receptors (40)
and is used in the treatment of hormone-dependent breast
cancer. Although tamoxifen is able to inhibit the action of
estradiol, it itself exhibits slight estrogenic activity and acts as
a partial agonist (41, 42), which is in agreement with our
findings. Fig. 2 illustrates the ability of tamoxifen to inhibit the
response of the screen to both 17b-estradiol and alkylphenolic
chemicals in a dose-dependent manner. This substantiates the
requirement for both the estrogen receptor and an active ligand
to stimulate the production of b-galactosidase.
Certain structural motifs are now realized to be important
for estrogenicity. Xenoestrogens are generally fat-soluble mono
or diphenolic chemicals in which hydrophobicity is achieved by
either chlorination (for example o, p9-DDT, o, p9-DDE, and
some polychlorinated biphenyls are all weakly estrogenic) or by
the addition of a bulky hydrocarbon side chain to themeta (3rd
carbon) or para (4th carbon) position of an otherwise unhin-
dered ring (such as alkylphenols). The present study indicates
that the size and degree of branching of the alkyl group, as well
as its position relative to the hydroxyl group on the phenol ring,
are also important features for estrogenic activity of APs and
illustrates the effectiveness of this yeast-based system in iden-
tifying structure-activity relationships of xenoestrogens. How-
ever, it should always be borne in mind that the chemical
structures illustrated within the figures represent only a two-
dimensional image. It is likely that certain aspects of the struc-
tures such as charge distribution and “twist” may produce
novel structural features that could only be revealed in three-
dimensional images and that may also be important in deter-
mining the estrogenic potency of this class of chemicals.
Estrogenicity requires that the alkyl group is composed of 3
or more carbons. The addition of each carbon increases the
hydrophobicity of the molecule, which may explain, in part,
why short chain alky groups (containing 3 or 4 carbons) are
active. A stepwise increase in activity then occurs with the
addition of each carbon (Fig. 3), but divergent activities occur
between different branching groups (Figs. 4–6). Only a limited
number of 4-secondary and 4-normal branching structures
were available to test, but the results indicate that they are
likely to be similar in potency. This is not surprising, given the
structural similarity of their alkyl groups. The 4-tert branching
structures, however, were generally much more potent, indi-
cating that the branching on the a-carbon (the carbon attached
to the phenol ring) may be an important feature for estrogenic-
ity. This observation is further supported by the fact that the
30-fold reduction in activity seen between 4-tert-octylphenol
and 4-nonylphenol may be due in part to the fact that branch-
ing also occurs in places outside the a-carbon in the case of
4-nonylphenol (43).
Activity was greatest with 4-tert-octylphenol (8 carbons), in
which 1,000 molecules produced a response similar to that
obtained by 1 molecule of 17b-estradiol, but 4-nonylphenol (9
carbons) was 30 times less active (Fig. 3). This drop in activity
only occurs in 4-tert-branching structures and therefore may be
due to the isomeric heterogeneity of 4-nonylphenol compared
with that of some other 4-alkylphenolic compounds. Recent
high-resolution gas chromatographic analyses of para-nonyl-
phenol have identified 22 para-isomers (43). Isomeric purity of
alkylphenolic chemicals is largely dependent on the nature of
the starting olefin. It is possible that due to the augmentation
of possible branching forms (44), 4-nonylphenol contains iso-
meric branching structures that are both greater in activity
and relatively inactive compared to 4-tert-octylphenol, result-
ing in an overall reduction in observed effect.
The position of alkylation on the phenolic ring (irrespective
of branching form) also affects estrogenicity, possibly because
this affects the alignment of the alkylphenol in the receptor.
The potent ortho-para directing influence of the hydroxyl group
on the phenol ring does not favor the formation of meta-iso-
mers. However, results from those meta-substituted alkylphe-
nols that were available, along with the data obtained from the
phenylphenols (Fig. 11), indicate that estrogenicity increases
as the alkyl group is moved from ortho to meta to para, respec-
tively (Fig. 7). The importance of the para position was further
illustrated by substitution of an existing alkylphenol with a
small inactive methyl group (Fig. 3). Exchanging places of a
methyl and a nonyl (9-carbon) group situated on the 2nd (ortho)
and 4th (para) position on the ring results in a reduction in
activity (Fig. 8) that is not entirely accounted for by the move-
ment of the active nonyl group away from the para position
alone. It seems, therefore, that the size and type of branching,
as well as the position of the alkyl group on the phenolic ring,
are key features in the estrogenicity of AP compounds.
Di-substitution with an alkyl group of 4 carbons or greater
greatly reduces or completely abolishes activity, which empha-
sizes the importance of an unhindered ring structure (Fig. 9).
Because no decrease in activity was observed between 4-non-
ylphenol and 2-methyl-4-nonylphenol, it seems that the alkyl
groups must be similar in size for this effect to be noticeable.
Substitution of the hydroxyl group also affects estrogenicity
of APs. The compounds tested in Fig. 10 are more relevant to
the biodegradation of alkylphenolic surfactants, such as nonyl-
phenol polyethoxylates (NPnEO, where n 5 6–40). The parent
surfactant itself is not active, but during sewage treatment,
APnEO are biodegraded via shortening of the ethoxylate chain
to short-chain ethoxylates and carboxylic acid derivatives and
finally APs (45), which are all estrogenic (24). Fig. 10 indicates
that short-chain ethoxylates are less active than the unsubsti-
tuted equivalent, but substitution of the hydroxyl group with a
similar-sized propylene oxide derivative results in a much
greater reduction in activity. As biodegradation of the primary
branched ethoxylated alkylphenols results in the production of
estrogenic metabolites, but secondary hydroxyl groups cannot
be oxidized to carboxylates by bacteriological activity,3 the
biodegradation of propoxylated alkylphenols is therefore less
likely to result in the formation of estrogenic intermediates.
Ethoxylated alkylphenolic compounds (APEs) comprise one
of the largest volume surfactants in production. Approximately
450 million pounds of APE surfactants were sold in the United
States in 1988 alone (46). APEs are used in both household and
institutional cleaning products (47). The four largest industrial
uses of APEs are in plastics (12) and elastomers, textiles (clean-
ing, spinning, weaving, finishing), agricultural chemicals (wet-
ters and emulsifiers), and paper (pulping). In the household
market the main reported uses of APEs are in laundry deter-
gents and hard-surface cleaners. In addition, nonylphenol poly-
ethoxylates are widely used as a spermicide in contraceptive
creams and jellies and in prophylactics. APEs have also been
found in hair-care products, including shampoos, hair color-
ings, and hair styling aids, and certain APs are used in the
manufacture of flavors and fragrances, all of which are possible
routes for human exposure.
The potential impact of AP compounds and other xenoestro-
gens on humans and wildlife is unclear but may be influenced
by factors such as the level and route of exposure, metabolism,
bioconcentration, lifestyle, and stage of development. Unlike
natural steroidal estrogens, many man-made xenoestrogens
are lipophilic and may bioaccumulate; in fish, an average
3 C. Green, personal communication.
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bioconcentration factor for nonylphenol would seem to be ap-
proximately 300 (48). Moreover, circulating xenoestrogenic
chemicals may not be recognized and sequestered by plasma
steroid-binding proteins such as sex hormone binding globulin
and a-feto protein (49), which are critical in preventing early
estrogen exposure of the fetus, and thus unmodulated action of
APs on target cells and tissues may occur. All these questions
must be addressed if the potential risk from exposure to xe-
noestrogens is to be determined with any accuracy.
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